Indoco Remedies Recommends Dividend of ₹0.20/Share, Reports Audited FY26 Results
Indoco Remedies Limited's Board approved audited financial results for FY26. The company recommended a dividend of ₹0.20 per equity share for FY26, subject to shareholder approval. The Board Meeting took place on May 7, 2026.
The announcement includes the audited financial results for the year and quarter, along with a dividend recommendation. This is material information for investors and affects the company's valuation and shareholder returns.
The announcement reports financial results and recommends a dividend. While a dividend recommendation is generally positive, the financial performance for the year shows a loss on a consolidated basis, making the overall sentiment neutral.
Indoco Remedies Limited announced the outcome of its Board Meeting held on May 7, 2026. The Board approved the audited financial results (Consolidated and Standalone) for the quarter and year ended March 31, 2026, along with the Auditors' Reports, which carried an unmodified opinion.
Key financial highlights for the year ended March 31, 2026, include Total Income from Operations of ₹1,68,607 lakhs (Standalone) and ₹1,84,865 lakhs (Consolidated). For the quarter ended March 31, 2026, Total Income from Operations stood at ₹45,948 lakhs (Standalone) and ₹47,557 lakhs (Consolidated).
The Board also recommended a dividend of ₹0.20 per equity share (face value ₹2) for the financial year 2025-2026, subject to shareholder approval at the upcoming 79th Annual General Meeting.
The financial results were presented in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with statutory auditors M/s. Gokhale & Sathe, Chartered Accountants, expressing an unmodified opinion.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.